TABLE 1.
Patient characteristics and comparison between the BCS and mastectomy groups
| Patient characteristics | All cases | BCS group | Mastectomy group | p-Value |
|---|---|---|---|---|
| Total patients [n (%)] | 206 | 90 (44) | 116 (56) | |
| Age [years; median (range)] | 49.1 (26–68) | 50.0 (27–68) | 47.6 (26–67) | 0.04 |
| Race [% (n)] | ||||
| Caucasian | 75 (155) | 73 (66) | 77% (89) | 0.92 |
| African American | 18 (37) | 20 (18) | 21% (24) | |
| Asian | 4 (9) | 4 (4) | 4% (5) | |
| Other | 2 (5) | 1 (1) | 1% (3) | |
| Clinical tumor size [cm; median (range)] | 6.0 (0–25) | 5.0 (1–14) | 7.0 (0–25) | <0.0001 |
| Clinical T stage (n = 204) [% (n)] | ||||
| 1a | 2 (5) | 2 (2) | 3 (3) | 0.0001 |
| 2 | 35 (73) | 51 (46) | 23 (27) | |
| 3 | 50 (104) | 41 (37) | 58 (67) | |
| 4 | 11 (22) | 4 (4) | 16 (18) | |
| Clinically node positive [% (n)] | 64 (131) | 61 (55) | 66 (76) | 0.47 |
| Clinical stage (n = 205) [% (n)] | ||||
| Ia | 1 (3) | 1 (1) | 2 (2) | 0.0006 |
| II | 47 (96) | 60 (54) | 36 (42) | |
| III | 44 (91) | 37 (33) | 49 (57) | |
| Inflammatory | 8 (16) | 1 (1) | 13 (15) | |
| Histologic grade [% (n)] | ||||
| I | 7 (15) | 10 (9) | 5 (6) | 0.36 |
| II | 47 (96) | 47 (42) | 44 (51) | |
| III | 46 (95) | 41 (37) | 50 (58) | |
| Indeterminate | 1 (3) | 2 (2) | 1 (1) | |
| Receptor status [% (n)] | ||||
| HR (+) | 60 (123) | 54 (49) | 64 (74) | 0.20 |
| HER2 (+) | 32 (66) | 31 (28) | 33 (38) | 0.88 |
| HR (+) HER2 (−) | 44 (90) | 40 (36) | 47 (54) | 0.53 |
| HR (−) HER2 (−) | 24 (50) | 29 (26) | 21 (24) | |
| HR (−) HER2 (+) | 16 (33) | 17 (15) | 16 (18) | |
| HR (+) HER2 (+) | 16 (33) | 14 (13) | 17 (20) | |
| Ki-67 [% (n)] | ||||
| Low (<10 %) | 24 (49) | 24 (19) | 29 (26) | 0.35 |
| Medium (10–25 %) | 30 (61) | 31 (24) | 36 (32) | |
| High (>25 %) | 34 (70) | 45 (35) | 34 (31) | |
| Indeterminate | 13 (26) | |||
| Residual cancer burden [% (n)] | n = 192 | n = 109 | n = 83 | |
| 0 | 26 (54) | 34 (28) | 24 (26) | 0.45 |
| 1 | 9 (18) | 10 (8) | 9 (10) | |
| 2 | 41 (84) | 41 (34) | 46 (50) | |
| 3 | 7 (14) | 16 (13) | 21 (23) | |
| Lymphovascular invasion [% (n)] | 17 (36) | 15 (13) | 20 (23) | 0.46 |
| Total receiving radiation [% (n)] | 83 (170) | 87 (78) | 79 (92) | 0.20 |
| Total receiving taxane [% (n)] | 5 (11) | 6 (5) | 5 (6) | 1 |
BCS breast-conserving surgery, HR hormone receptor, HER2 human epidermal growth factor receptor 2
a
As of data lock in February 2012